retatrutide clinical trial outcomes A new from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide approval: FDA status, clinical

Commenting on the study for Science Media Centre, Professor of Cancer Epidemiology Paul Pharoah said, While these results suggest that GLP1 receptor agonist have an effect on cancer risk the presence of an association does not mean that the association is a causal one. An observational study, no matter how carefully conducted, cannot replicate a randomised controlled trial, which would be regarded as gold standard to evaluate the effects of a drug. Inflammation We said some of the documented effects of GLP-1RAs were surprising, and that pretty much all bodily systems could be fair game

Diabetol Metab Syndr 18 , 29 (2026)

10.1172/JCI81335 [DOI] [PMC free article] [PubMed] [Google Scholar] Gilbert, M

No stomach damage, no addiction, no organ toxicity